News & Updates

Show Multimedia Only

Which factors predict mortality in advanced HCC?

Which factors predict mortality in advanced HCC?

A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).

01 Mar 2024

Hepatitis E vaccine offers durable protection

Hepatitis E vaccine offers durable protection

Vaccination against hepatitis E appears to provide up to 10 years of protection, with vaccine-induced antibodies persisting for at least 8.5 years, as shown in a study from China.

Hypercholesterolemia linked to poor prognosis in primary biliary cholangitis

Hypercholesterolemia linked to poor prognosis in primary biliary cholangitis

Hypercholesterolemia linked to poor prognosis in primary biliary cholangitis

In patients with primary biliary cholangitis (PBC), elevated total cholesterol levels are associated with dysregulation of lipid metabolism and may lead to poor clinical outcomes, as shown in a study.

High levels of salt added to food up CKD risk

High levels of salt added to food up CKD risk

Frequently adding salt to food significantly increases the risk of chronic kidney disease (CKD) in the general population, according to a recent study.

Alcohol abstinence boosts overall survival in alcohol-associated cirrhosis

Alcohol abstinence boosts overall survival in alcohol-associated cirrhosis

Abstinence from alcohol may dramatically increase survival rates for individuals with alcohol-related cirrhosis, as reported in a study.

Dietary niacin may protect against death in NAFLD

Dietary niacin may protect against death in NAFLD

Dietary niacin intake may benefit individuals with nonalcoholic fatty liver disease (NAFLD), with a study suggesting that a higher intake lowers the risk of mortality.

13 Feb 2024

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape

In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.

13 Feb 2024

Larsucosterol for hepatitis proves safety in phase IIa trial

Larsucosterol for hepatitis proves safety in phase IIa trial

Treatment with larsucosterol is safe and well tolerated in patients with alcohol-associated hepatitis (AH), as shown in a recent study.

01 Feb 2024

Noncontrast-enhanced MRI superior to US but less cost-effective for HCC screening

Noncontrast-enhanced MRI superior to US but less cost-effective for HCC screening

Noncontrast-enhanced magnetic resonance imaging (NCEMRI) demonstrates superiority over ultrasonography (US) for the surveillance of hepatocellular carcinoma (HCC) in at-risk populations, although this strategy is more expensive than US, according to a Singapore study.

31 Jan 2024

Vaccines protect liver disease patients against severe COVID-19

Vaccines protect liver disease patients against severe COVID-19

Patients with liver disease develop antibodies and T-cell responses following three shots of COVID-19 vaccines, while those who have been infected with SARS-CoV-2 develop mild symptoms only, reports a recent study.

20 Jan 2024

Something went wrong.